Broad neutralization of SARS-related viruses by human monoclonal antibodies

doi:10.1126/science.abc7424

GSTDTAP > 气候变化

DOI	10.1126/science.abc7424
	Broad neutralization of SARS-related viruses by human monoclonal antibodies
	Anna Z. Wec; Daniel Wrapp; Andrew S. Herbert; Daniel P. Maurer; Denise Haslwanter; Mrunal Sakharkar; Rohit K. Jangra; M. Eugenia Dieterle; Asparouh Lilov; Deli Huang; Longping V. Tse; Nicole V. Johnson; Ching-Lin Hsieh; Nianshuang Wang; Juergen H. Nett; Elizabeth Champney; Irina Burnina; Michael Brown; Shu Lin; Melanie Sinclair; Carl Johnson; Sarat Pudi; Robert Bortz; Ariel S. Wirchnianski; Ethan Laudermilch; Catalina Florez; J. Maximilian Fels; Cecilia M. O’Brien; Barney S. Graham; David Nemazee; Dennis R. Burton; Ralph S. Baric; James E. Voss; Kartik Chandran; John M. Dye; Jason S. McLellan; Laura M. Walker
	2020-08-07
发表期刊	Science
出版年	2020
英文摘要	As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protective antibodies. Wec et al. isolated and characterized hundreds of antibodies against the viral spike protein of SARS-CoV-2 from the memory B cells of a survivor of the 2003 outbreak caused by the related coronavirus, SARS-CoV. In both of these viruses, the spike protein facilitated viral entry by binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells. The antibodies targeted multiple sites on the spike protein, but of nine antibodies that showed strong cross-neutralization, eight targeted the domain that binds to ACE2. These eight antibodies also neutralized a bat SARS-related virus. Illuminating the epitopes on the viral spike protein that bind cross-neutralizing antibodies could guide the design of broadly protective vaccines. Science , this issue p. [731][1] Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent severe acute respiratory syndrome (SARS) donor and identified 200 SARS coronavirus 2 (SARS-CoV-2) binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recall of preexisting memory B cells elicited by prior HCoV infections. Several antibodies potently cross-neutralize SARS-CoV, SARS-CoV-2, and the bat SARS-like virus WIV1 by blocking receptor attachment and inducing S1 shedding. These antibodies represent promising candidates for therapeutic intervention and reveal a target for the rational design of pan-sarbecovirus vaccines. [1]: /lookup/doi/10.1126/science.abc7424
领域	气候变化 ; 资源环境
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/288028
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Anna Z. Wec,Daniel Wrapp,Andrew S. Herbert,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies[J]. Science,2020.
APA	Anna Z. Wec.,Daniel Wrapp.,Andrew S. Herbert.,Daniel P. Maurer.,Denise Haslwanter.,...&Laura M. Walker.(2020).Broad neutralization of SARS-related viruses by human monoclonal antibodies.Science.
MLA	Anna Z. Wec,et al."Broad neutralization of SARS-related viruses by human monoclonal antibodies".Science (2020).